Introduction to Mesalazine and Ulcerative Colitis
Mesalazine, also referred to as mesalamine, is an essential first-line treatment for patients suffering from mild-to-moderate ulcerative colitis (UC). This chronic inflammatory bowel disease is characterized by persistent inflammation of the colon's mucosa, typically beginning in the rectum and potentially extending proximally. The importance of adhering to mesalazine therapy cannot be overstated, as consistent use is crucial for both inducing and maintaining remission in patients. However, real-world adherence to this medication is often less than optimal, influenced by a variety of factors including behavioral tendencies, cultural beliefs, treatment regimens, financial constraints, and the healthcare system's structure. While much of the research on mesalazine adherence has focused on populations in Europe and North America, there is a notable lack of data from North African cohorts, particularly in Morocco, where specific cultural and socioeconomic factors may further complicate adherence.
Study Overview and Key Findings
This study aimed to investigate the factors contributing to mesalazine nonadherence in a cohort of Moroccan patients diagnosed with mild-to-moderate UC. Conducted over a two-year period at the Mohammed VI University Hospital Center in Marrakech, the retrospective descriptive study evaluated 30 adult patients, comprised of 23 females and 7 males, aged between 23 and 57 years. The results revealed that while 66.7% of patients exhibited good adherence to their prescribed mesalazine regimen, a concerning 33.3% were deemed poorly adherent, taking less than 80% of their prescribed doses. Among the poorly adherent patients, the most common reason cited for nonadherence was the cessation of treatment during asymptomatic periods, reported by 60% of this subgroup. Other factors influencing nonadherence included the use of herbal alternatives (20%), fear of medication (10%), and forgetfulness (10%). The study also highlighted that a significant number of patients experienced a high pill burden, defined as taking four or more tablets daily, which was associated with adherence challenges.
Financial barriers further exacerbated the issue, with 26.7% of patients reporting difficulties in regularly purchasing mesalazine due to cost. Notably, targeted counseling efforts were implemented for those identified as poorly adherent, resulting in a 70% improvement in adherence among this group following the intervention. This finding underscores the critical role of patient education and structured support in enhancing adherence to maintenance therapy.
The implications of this study are significant, as they provide insight into the multifaceted nature of medication adherence in chronic conditions like UC. Understanding the interplay of behavioral, cultural, and systemic factors can inform the development of tailored interventions aimed at improving adherence rates among patients. By simplifying dosing regimens, enhancing access to affordable medications, and fostering a supportive environment for patient education, healthcare providers can play a pivotal role in optimizing long-term adherence and ultimately improving patient outcomes in real-life clinical settings.
As reported by cureus.com.
